Document is current
Any future updates will be listed below
-
Authors
Szebeni, Janos https://orcid.org/0000-0003-1738-797X
Storm, Gert
Ljubimova, Julia Y.
Castells, Mariana
Phillips, Elizabeth J.
Turjeman, Keren
Barenholz, Yechezkel
Crommelin, Daan J. A. https://orcid.org/0000-0003-0216-5039
Dobrovolskaia, Marina A. https://orcid.org/0000-0002-4233-9227
-
Funding
Funding for this research was provided by:
European Union Horizon 2020; the Department of Nanobiotechnology and Regenerative Medicine, Faculty of Health, Miskolc
none
U.S. Department of Health & Human Services | National Institutes of Health (R01CA206220)
U.S. Department of Health & Human Services | National Institutes of Health (UAI109565)
U.S. Department of Health & Human Services | National Institutes of Health (P50GM115305, R01HG010863, R01AI152183, R21AI139021, U01AI154659)
U.S. Department of Health & Human Services | DHHS Office of the Secretary (75N91019D00024)
- License Information
-
More Information
Article History
Received: 2 April 2021
Accepted: 4 January 2022
First Online: 7 April 2022
Competing interests
: G.S., K.T., Y.B., J.Y.L., M.C., M.A.D. and D.J.A.C. declare no competing interests. E.J.P. receives royalties and consulting fees from UpToDate, Janssen, Vertex, Biocryst and Regeneron; she is co-director of IIID Pty Ltd, which holds a patent for HLA-B*57:01/abacavir Australia and Canada testing for abacavir hypersensitivity (Canadian Patent 2,475,784 and Australian Patent 2003202657) and she has a patent pending for the Detection of Human Leukocyte Antigen-HLA-A*32:01/vancomycin in the U.S. (PCT/US2020/018420) in connection with Diagnosing Drug Reaction with Eosinophilia and Systemic Symptoms without any financial remuneration or direct relationship to the submitted work. J.S. is affiliated with SeroScience Ltd, an immune-toxicity-evaluating CRO.
Free to read: This content has been made available to all.
